Leiner names new COO
This article was originally published in The Tan Sheet
Executive Summary
Gerry Perez joins Leiner as COO, firm reports Dec. 14. Perez has served as Boehringer Ingelheim senior VP since 1995, previously was technical operations VP at Bayer. Supplement/OTC manufacturer also announces it has reached agreement in principle with lenders to extend forbearance period for fifth time until completion of Chapter 11 financial restructuring plan, slated for early 2002 (1"The Tan Sheet" Nov. 12, p. 11)...
You may also be interested in...
Leiner Chapter 11 Plan To Include New Capital, Credit, Debt Restructuring
Leiner Health Products will use a tentative $20 mil. equity investment to support ongoing operations as it prepares to seek Chapter 11 protection in early 2002, the company stated
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.